Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Hydroxychloroquine and the Coronavirus: Connecting the Dots Through the Biology Knowledge Graph

Posted on April 16th, 2020 by

COVID-19

It would be hard to miss the current interest in finding effective treatment for COVID-19. In this regard, the combination of hydroxychloroquine (HCQ) with azithromycin is getting a great deal of attention. HCQ, sold under the brand name Plaquenil, is a well-known anti-malarial drug, while azithromycin is a common antibiotic that is usually used for the treatment of strep throat (the widely used Zithromax, Z-Pak).

(more…)

Five drug development strategies to combat 2019 novel coronavirus

Posted on April 15th, 2020 by

COVID-19

This article was originally published on Feb 28, 2020, and has been updated on Apr 13, 2020.

Coronavirus disease 19 (COVID-19) has rapidly spread from its starting point in Wuhan, China. As of February 23, 2020, a total of 32 countries and territories have reported 78,811 cases (98% in China) and 2462 deaths [1]. The international scientific community is in a race against time. Researchers across the globe are collaborating to develop antivirals and vaccines to contain the spread of 2019 novel coronavirus (SARS-CoV-2).

(more…)

Increase visibility of your COVID-19 clinical findings with SSRN

Posted on April 9th, 2020 by

COVID-19

Quickly communicating pertinent clinical information, such as research regarding patient treatments, is critical during public health crises like the ongoing novel coronavirus disease 2019 (COVID-19) pandemic. However, the standard publication process for scientific articles, including peer review, can take as long as two years, and this slow pace of scientific publication can interfere with response to the public health emergency. A faster means for relaying information on COVID-19 research is required.

Fortunately, a more expedient way to disseminate ongoing research information is already available through the use of preprint servers, such as Elsevier’s SSRN. With preprint server publication, research becomes available online pre–peer review for public review and comment as soon as the server verifies certain standards are met (e.g., content is complete, patient privacy was protected). The time taken between article submission and online publication is much faster, typically in the range of hours to days.

(more…)

Integration and visualization of COVID-19 molecular mechanisms using Pathway Studio

Posted on April 6th, 2020 by

COVID-19

Integrating the rich information from multi-omics data has been a popular approach to drugs discovery and development against novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To facilitate the integrative analysis and power the global researchers, we have constructed various models that contain biomedical pathways information for SARS-CoV and SARS-CoV-2. Now they are available for public access.

(more…)

Webinar: Accelerating drug discovery by building and turning high-quality data into actionable insights

Posted on April 6th, 2020 by

Chemistry

Drug discovery is a time-consuming and costly process (and all the more costly because it’s time-consuming). One of the hopes of the era of Big Data has been that having access to a wealth of scientific information could help speed the discovery process. However, the data itself has proven to come with many challenges. Medicinal chemists like myself are often frustrated in our attempts to integrate and work with disparate and unstructured sets of data.

(more…)

Analgesics Use and the Coronavirus: Finding Answers Through Biological Knowledge Graph

Posted on March 31st, 2020 by

COVID-19

a. 121 ARDS-induced proteins whose activity and/or abundance are upregulated by ARDS
(more…)

  1. 1
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7
  7. 77


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.